Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008560 | 1.00 | LMNA (0.41) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL10004082 | 0.91 | CA1 (0.38) | SMN1; SMN2KMT2AMEN1RAB9ACA2 | |
| SCHEMBL1811991 | 0.88 | HPGD (0.39) | LMNAALDH1A1KMT2AMEN1NPSR1 | |
| SCHEMBL2008909 | 0.87 | LMNA (0.39) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL2008911 | 0.87 | LMNA (0.39) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL1807789 | 0.87 | CYP1A2 (0.37) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL7023448 | 0.87 | APP (0.32) | ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL643837 | 0.86 | BTN3A1 (0.40) | LMNANPSR1MAPK1POLBTDP1 | |
| SCHEMBL5996997 | 0.86 | BTN3A1 (0.40) | LMNANPSR1MAPK1POLBTDP1 | |
| SCHEMBL6708631 | 0.85 | LMNA (0.42) | LMNAALDH1A1KDM4ESMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465641-B1 | METHOD INCLUDES CONTACTING PHOSPHOROUS OXYCHLORIDE WITH A HALOPHENYL MOIETY FOLLOWED BY CONTACTING THE RESULTING HALOPHENYLPHOSPHORODICHLORIDATE WITH A CARBOXY-PROTECTED AMINO ACID AND FINALLY CONTACTING THE RESULTING HALOPHENYLCARBOXY | PARKER HUGHES INSTITUTE | 2002-10-15 | — | — | US | claimed |
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-2203462-B2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2024-05-02 | — | — | US | disclosed |
| EP-2801580-B1 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7964580-B2 | Nucleoside phosphoramidate prodrugs | PHARMASSET, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7772197-B2 | 1,3,5-triazines for treatment of viral diseases | 1,3,5-Triazines for Treatment of Viral Diseases (US) | 2010-08-10 | — | — | US | disclosed |
| US-7642247-B2 | 1,3,5-triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-6482805-B2 | AZT derivatives exhibiting spermicidal and anti-viral activity | PARKER HUGHES INSTITUTE | 2002-11-19 | — | — | US | disclosed |
| US-6465641-B1 | METHOD INCLUDES CONTACTING PHOSPHOROUS OXYCHLORIDE WITH A HALOPHENYL MOIETY FOLLOWED BY CONTACTING THE RESULTING HALOPHENYLPHOSPHORODICHLORIDATE WITH A CARBOXY-PROTECTED AMINO ACID AND FINALLY CONTACTING THE RESULTING HALOPHENYLCARBOXY | PARKER HUGHES INSTITUTE | 2002-10-15 | — | — | US | disclosed |
| US-6407078-B1 | THYMINE RING (E.G. AZIDOTHYMIDINE, AZT) THAT HAS 5-HALO, 6-ALKOXY SUBSTITUTION | PARKER HUGHES INSTITUTE | 2002-06-18 | — | — | US | disclosed |
| US-20020025922-A1 | AZT derivatives exhibiting spermicidal and anti-viral activity | UCKUN, FATIH M. | 2002-02-28 | — | — | US | disclosed |
| US-20020022600-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | UCKUN, FATIH M. | 2002-02-21 | — | — | US | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| US-6191120-B1 | CONTRACEPTIVE; VIRICIDE | WAYNE HUGHES INSTITUTE | 2001-02-20 | — | — | US | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022600-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | TYMP, DUT, UNG | LMNA 2473/4885ALDH1A1 919/4885KDM4E 789/4885 |
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | LMNA 2469/4885ALDH1A1 1168/4885KDM4E 4570/4885 |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | LMNA 2469/4885ALDH1A1 1168/4885KDM4E 4570/4885 |
| US-20020025922-A1 | AZT derivatives exhibiting spermicidal and anti-viral activity | TYMP, DUT, UNG | LMNA 2473/4885ALDH1A1 919/4885KDM4E 789/4885 |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | LMNA 2469/4885ALDH1A1 1168/4885KDM4E 4570/4885 |
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | LMNA 898/4885ALDH1A1 1940/4885KDM4E 1279/4885 |
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | LMNA 2469/4885ALDH1A1 1168/4885KDM4E 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.